期刊
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
卷 37, 期 3, 页码 164-172出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/cbr.2021.0286
关键词
radionuclide theranostics; hematological toxicity; myelodysplasia; acute leukemia; risk stratification; radiogenomics
Emerging genomic analytic techniques in cancer patients can potentially define the risks of myelo dysplastic syndrome and acute leukemia following targeted radionuclide therapy. Identifying patients at heightened risk of hematologic toxic complication using novel genomic technology before radionuclide therapy can ameliorate myelotoxicity. Personalized precision nuclear oncology aims to minimize toxicity while preserving optimal individualized efficacy.
Emergent genomic analytic techniques in patients with cancer offer the potential to define the risk of myelo dysplastic syndrome (MDS) and acute leukemia (AL) manifesting following targeted radionuclide therapy of metastatic lymphoma, neuroendocrine tumors (NETs), and prostate cancer. Characterization of the genetic profile will allow risk stratification of patients before theranostic radionuclide management of advanced cancers and offers the opportunity to minimize toxicity while preserving optimal individualized efficacy in the practice of personalized precision nuclear oncology. Our review of a single-center experience of prospective radionuclide theranostic management of metastatic non-Hodgkin lymphoma (NHL), NETs, and castration-resistant prostate cancer (metastatic castrate-resistant prostate cancer [mCRPC]) over the past decade, and comparison with published studies, shows that while the risk of significant myelotoxicity is generally low, at <3%, the consequences in the small minority of patients who develop MDS or AL are substantial, and survival is poor. Timely identification of patients at heightened risk of hematologic toxic complication, using novel genomic technology before institution of radionuclide therapy, will facilitate amelioration of myelotoxicity. In current clinical practice, the minimal hematological toxicity of chemo-free theranostic management of advanced cancer is significantly less compared with newly adopted chemotherapy -immunotherapy regimens, and the financial toxicity associated with these novel agents is avoided.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据